Related Experiment Video
Updated: Jun 29, 2025
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
12.0K
Targeting nuclear receptors for NASH/MASH: From bench to bedside
1Department of Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Liver Research (Beijing, China)
|March 28, 2024
Summary
Nuclear receptor ligands are promising drug candidates for treating metabolic dysfunction-associated steatohepatitis (MASH). This review covers nuclear receptors in clinical trials and preclinical studies for MASH treatment.
Area of Science:
- Hepatology
- Endocrinology
- Pharmacology
Background:
- Metabolic dysfunction-associated steatohepatitis (MASH) signifies a critical stage of liver injury in metabolic dysfunction-associated steatotic liver diseases (MASLD).
- Currently, no FDA-approved pharmacological treatments exist for MASH, necessitating the development of novel therapeutic strategies.
- MASH pathogenesis involves complex interactions of hepatic metabolism, inflammation, and fibrosis.
Purpose of the Study:
- To review the current understanding of nuclear receptors (NRs) as therapeutic targets for MASH.
- To highlight NRs undergoing clinical trials and those with promising preclinical data for MASH treatment.
Main Methods:
- Literature review of preclinical and clinical studies on nuclear receptors and MASH.
- Analysis of NR mechanisms in regulating liver metabolism, inflammation, and fibrogenesis.
- Identification of NR ligands as potential pharmacological agents.
Main Results:
- Nuclear receptors (NRs) regulate key pathways in liver metabolism and inflammation.
- NR ligands, including hormones, lipids, and synthetic compounds, modulate gene transcription.
- NR ligands are emerging as the most promising drug candidates for MASH treatment, with several in clinical trials.
Conclusions:
- Nuclear receptors represent a highly promising therapeutic avenue for MASH.
- Targeting NRs offers a multifaceted approach to address the complex drivers of MASH.
- Further research into NR ligands is crucial for developing effective MASH pharmacotherapies.
Related Concept Videos
01:31Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
01:45Regulation of Nuclear Protein Sorting
2.4K
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
2.4K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:26Targets for Drug Action: Overview
6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
659
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
659